CR7571A - Tratamiento de la hipertension en mujeres que reciben terapia de reemplazo hormonal - Google Patents

Tratamiento de la hipertension en mujeres que reciben terapia de reemplazo hormonal

Info

Publication number
CR7571A
CR7571A CR7571A CR7571A CR7571A CR 7571 A CR7571 A CR 7571A CR 7571 A CR7571 A CR 7571A CR 7571 A CR7571 A CR 7571A CR 7571 A CR7571 A CR 7571A
Authority
CR
Costa Rica
Prior art keywords
replacement therapy
hypertension
treatment
women receiving
hormonal replacement
Prior art date
Application number
CR7571A
Other languages
English (en)
Inventor
H Karara Adel
Original Assignee
Bayer Shering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Shering Pharma Ag filed Critical Bayer Shering Pharma Ag
Publication of CR7571A publication Critical patent/CR7571A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un metodo para reducir la tension arterial y lograr el efecto de una terapia de reemplazo hormonal (TRH) en una mujer hipertensa que recibe TRH, y que comprende administrar a la mujer dosis efectivas de drospirenona y un estrogeno. En una realizacion, la mujer ya esta tomando medicacion antihipertensiva cuando se inicia el metodo.
CR7571A 2002-04-26 2004-11-05 Tratamiento de la hipertension en mujeres que reciben terapia de reemplazo hormonal CR7571A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37543902P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
CR7571A true CR7571A (es) 2006-02-07

Family

ID=29270642

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7571A CR7571A (es) 2002-04-26 2004-11-05 Tratamiento de la hipertension en mujeres que reciben terapia de reemplazo hormonal

Country Status (23)

Country Link
US (1) US20040034001A1 (es)
EP (2) EP1499323A1 (es)
JP (1) JP2005528408A (es)
KR (1) KR20040104632A (es)
CN (1) CN1649596A (es)
AU (2) AU2003239162A1 (es)
BR (1) BR0309780A (es)
CA (1) CA2483554A1 (es)
CR (1) CR7571A (es)
EC (1) ECSP045456A (es)
HK (1) HK1079997A1 (es)
HR (1) HRP20041121A2 (es)
IL (1) IL164808A0 (es)
ME (1) MEP35908A (es)
MX (1) MXPA04010682A (es)
NO (1) NO20045147L (es)
NZ (1) NZ548754A (es)
PL (1) PL372055A1 (es)
RS (1) RS93804A (es)
RU (1) RU2373940C2 (es)
UA (1) UA87437C2 (es)
WO (1) WO2003090755A1 (es)
ZA (1) ZA200409548B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE102004016779A1 (de) * 2004-04-01 2006-01-19 Schering Ag Drospirenonhaltige Zubereitungen zur transdermalen Anwendung
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
US20090035373A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same
US20090035374A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same
KR20130097073A (ko) * 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US5001113A (en) 1987-10-14 1991-03-19 Merck & Co., Inc. Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US6083528A (en) 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
KR0156678B1 (ko) 1996-01-11 1998-10-15 이상윤 안지오텐신 전환효소 저해제
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DK1380301T3 (da) * 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
AU2001225413B2 (en) * 2000-01-18 2005-06-23 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormone replacement therapy
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins

Also Published As

Publication number Publication date
MEP35908A (en) 2011-02-10
MXPA04010682A (es) 2004-12-13
KR20040104632A (ko) 2004-12-10
WO2003090755A1 (en) 2003-11-06
HK1079997A1 (zh) 2006-04-21
NO20045147L (no) 2005-01-18
AU2008203497A1 (en) 2008-08-28
IL164808A0 (en) 2005-12-18
BR0309780A (pt) 2005-03-22
UA87437C2 (ru) 2009-07-27
NZ548754A (en) 2008-06-30
EP1499323A1 (en) 2005-01-26
HRP20041121A2 (en) 2005-02-28
US20040034001A1 (en) 2004-02-19
ZA200409548B (en) 2010-05-26
AU2003239162A1 (en) 2003-11-10
ECSP045456A (es) 2005-01-28
RU2373940C2 (ru) 2009-11-27
CN1649596A (zh) 2005-08-03
RU2004134571A (ru) 2005-07-10
EP1982719A1 (en) 2008-10-22
CA2483554A1 (en) 2003-11-06
RS93804A (sr) 2006-10-27
JP2005528408A (ja) 2005-09-22
PL372055A1 (en) 2005-07-11

Similar Documents

Publication Publication Date Title
ECSP045456A (es) Tratamiento de la hipertensión en mujeres que reciben terapia de reemplazo hormonal
Andersch et al. Progesterone treatment of premenstrual tension—a double blind study
DK0836506T4 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
ATE312635T1 (de) Ventilanordnung
NZ520015A (en) Hydroxide-releasing agents as skin permeation enhancers
PT1011682E (pt) Contraceptivo hormonal
DK0782450T3 (da) Anvendelse af aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ androgenmangel hos mænd
US7985195B2 (en) Body or plant part dressing
ATE371462T1 (de) Verbesserung der herstellung von endogenen gonadotropin
DK1558265T3 (da) Anvendelse af dropspirenon til behandling af hypertension
UY29274A1 (es) Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida
ATE380545T1 (de) Pharmazeutische zubereitung mit verzögerter freisetzung zur oralen wirkstoffverabreichung
AR036970A1 (es) Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
ECSP056009A (es) Regimenes contraceptivos transdermicos extendidos
ATE440601T1 (de) Hydroxypyridinone zur lokalen behandlung von hautmikrozirulationsstírungen
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
DK1585513T3 (da) Anvendelse af docosahexaensyre som aktivt stof til behandling af lipodystrofi
AR039547A1 (es) Terapia de reemplazo hormonal
ATE441431T1 (de) Behandlung von nicht-septischen patienten mit verbrennungen zweiten grades mittels verabreichung von aktiviertem protein c
BR0314959A (pt) Emplastro transdérmico de 17beta-estradiol/levonorgestrel para terapia de reposição hormonal
JP3243194U (ja) 指用固定湿布
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento
UY29861A1 (es) Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
RU2008149412A (ru) Применение дроспиренона для предотвращения высокого кровяного давления у пациентов с прегипертонией

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)